Florida’s House Bill (HB) 21, enacted to help combat opioid abuse, contains several noteworthy changes to Florida law that impact the dispensing of opioids.
Effective July 1, 2018, dispensing providers must consult Florida’s Prescription Drug Monitoring Program (PDMP) prior to dispensing controlled substances to patients, and must report any controlled substances dispensed in the PDMP by the following business day. The new dispensing requirements are discussed in further detail below:
A prescriber or dispensing provider who willfully and knowingly fails to record the dispensing of controlled substances under this section commits a misdemeanor of the first degree.
HB 21 also amends various other sections of Florida law to increase the regulations surrounding the prescribing and dispensing of controlled substances. This Alert does not address all new requirements implemented under HB 21.
For more information on Foley’s Health Care Industry Teams including the team, publications, and other materials, visit foley.com/health-care.
The foregoing was prepared for general information purposes only. This information is not legal advice and is not to be acted upon as such.
 Fla. Stat. § 893.055(8).
 For purposes of this subsection, a ‘nonopioid controlled substance’ is a controlled substance that does not contain any amount of a substance listed as an opioid in Florida Statutes section 893.03 or 21 U.S.C. section 812.
 Fla. Stat. § 893.055(3)(a).
 Id. § 893.055(9).